Literature DB >> 33039230

Covid-19 associated Guillain-Barre Syndrome: Contrasting tale of four patients from a tertiary care centre in India.

Satyan Nanda1, Rahul Handa2, Atul Prasad1, Rajiv Anand1, Dhruv Zutshi1, Sujata K Dass1, Prabhjeet Kaur Bedi1, Aarti Pahuja1, Pankaj Kumar Shah1, Bipan Sharma1.   

Abstract

BACKGROUND: Globally, more than 12 million people have been infected with COVID -19 infection till date with more than 500,000 fatalities. Although, Covid-19 commonly presents with marked respiratory symptoms in the form of cough and dyspnoea, a neurotropic presentation has been described of late as well.
OBJECTIVE: In this brief communication we report four cases of Covid-19 who presented to our hospital with features suggestive of Guillain-Barre Syndrome (GBS). DISCUSSION: The mechanisms by which SARS-CoV-2 causes neurologic damage are multifaceted, including direct damage to specific receptors, cytokine-related injury, secondary hypoxia, and retrograde travel along nerve fibres. The pathogenesis of GBS secondary to Covid-19 is not well understood. It is hypothesised that viral illnesses related GBS could be due to autoantibodies or direct neurotoxic effects of viruses.
CONCLUSION: Nervous system involvement in Covid-19 may have been grossly underestimated. In this era of pandemic, it is very important for the physicians to be aware of association of GBS with Covid-19, as early diagnosis and treatment of this complication could have gratifying results. To the best of our knowledge, this is the first such case series of Guillain-Barre Syndrome associated with Covid-19 to be reported from India.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33039230      PMCID: PMC7493759          DOI: 10.1016/j.ajem.2020.09.029

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


Introduction

Globally, more than 12 million people have been infected with COVID −19 infection till date with more than 500,000 fatalities [1]. Although, evolution in COVID-19 research is taking place at a rapid pace, new findings have to be thoroughly checked before any conclusion or treatment protocol is made or modified [2]. Although, Covid-19 commonly presents with marked respiratory symptoms in the form of cough and dyspnoea, a neurotropic presentation has been described of late as well [3]. Guillain Barre Syndrome (GBS) is best described as an acute inflammatory polyradiculoneuropathy clinically characterised by areflexia and progressive weakness of arms and legs. Though, many rare variants of GBS have been described, the commonly observed subtypes such as Acute Motor Axonal Neuropathy (AMAN), Acute Motor Sensory Axonal Neuropathy (AMSAN) and Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) tend to fulfil the above-mentioned criteria [4]. In this brief communication we report four cases of Covid-19 who presented to our hospital with features suggestive of GBS.

Case 1

A 55-year-old female with background history of Diabetes Mellitus, Hypertension and Cholelithiasis presented with chief complaints of fever 10 days back lasting for 3 days, pain abdomen for 5 days; acute onset rapidly progressive symmetric weakness of all four limbs for 3 days (lower limbs followed by upper limbs). There was no history suggestive of cranial nerve, bowel or bladder involvement. On examination, patient was hemodynamically stable with 98% oxygen saturation (SpO2) on room air. Cranial nerve examination was normal. Motor examination revealed generalised hypotonia, Grade 2/5 power in both lower limbs proximally and Grade 3/5 distally, while both upper limbs power was grade 4/5 proximally and grade 3/5 distally as per Medical Research Council (MRC) grading. Deep tendon reflexes were universally absent and plantar response was flexor bilaterally. Sensory examination was normal. Her single breath count (SBC) was 26. Her routine blood investigations including complete blood count, liver and kidney function tests were normal. Viral markers including Human Immunodeficiency Virus, Hepatitis B Surface antigen (HBsAg) and Hepatitis C Virus (HCV) antibody were negative. Serum vitamin B12 levels and Thyroid function tests were normal whereas Glycosylated Hemoglobin (HbA1c) was elevated (9.4 %). Covid-19 testing was positive by reverse transcription polymerase chain reaction (RT-PCR). Inflammatory markers were universally elevated (Table 1, Table 2 ). Chest X ray was normal. Contrast enhanced Magnetic Resonance Imaging (MRI) of the spine was suggestive of degenerative changes in the spine (Table 2). Nerve Conduction Study (NCS) of both upper and lower limbs was suggestive of pure motor axonal polyneuropathy. CSF examination done on fourth day of hospitalisation showed albumino-cytological dissociation (Table 2). After informed consent the patient was started on IV Immunoglobulin (IVIG): 0.4 g/kg body weight per day for five days. In view of a possibility of Covid-19 associated hypercoagulable state (elevated D Dimer) she was also given therapeutic anticoagulation. There was no further progression of her symptoms after starting IVIG and the patient was discharged after 10 days of hospital stay with Grade 4/5 power in both lower limbs and Grade 4+/5 power in both upper limbs.
Table 1

Clinical and laboratory parameters of four cases presenting with Covid-19 associated GBS.

CaseOnset of neurological symptomsComorbiditiesCranial nerve involvementRespiratory involvementCRP levels (mg/L)
Ferritin levels (ng/ml)
IL-6 levels
D-dimer (FEU/ml)
LDH levels (U/L)
Normal: <5Normal: 21.8–274Normal: 0–7Normal: 0–0.5Normal: 135–214
110 days after onset of feverDiabetes mellitusNoNo9.43828.212.19278
Hypertension
Cholelithiasis
26 days after onset of feverHypertensionNoYes5048210.215.19518
SBC = 12
3One week after the onset of cough and sore throatDiabetes mellitusNoNo34.4156044.715.49478
Hypertension
Chronic kidney disease on maintenance haemodialysis
410 days after the onset of feverHypertensionYes (Bilateral facial nerve palsy)No0.963224.750.32278
Table 2

Laboratory parameters, Imaging and clinical outcomes of four cases presenting with Covid-19 associated GBS.

CaseChest X rayNCS findingsCSFMRI spineTreatmentOutcome
1NormalPure motor axonal polyneuropathyProtein: 54 mg% Glucose:114 mg%Mild degenerative changes.IVIG: 2 g/kg over 5 daysGood improvement (Able to walk independently at discharge)
Cells = 5 cells/cmm; all lymphocytesNo Cord changes
No nerve root enhancement
2Ill-defined inhomogeneous infiltrates involving predominantly the upper lobesSevere demyelinating sensorimotor polyneuropathy affecting all 4 limbs with evidence of conduction block involving both ulnar nerves.Protein: 74 mg% Glucose:110 mg%Mild degenerative changes.IVIG: 2 g/kg over 5 days with supportive treatmentDeteriorated over the course of treatment.
Cells = 0 cells/cmm.No Cord changes
No nerve root enhancementDay 2 into IVIg therapy, power in all 4 limbs had reduced to grade 1/5 and patient developed severe respiratory distress requiring intubation and mechanical ventilation.
His respiratory involvement due to Covid-19 also continued to worsen and the patient expired after
7 days of hospital admission.
3NormalAxonal sensorimotor polyneuropathy affecting all 4 limbsProtein: 84 mg% glucose: 94 mg%Mild degenerative changes.IVIG: 2 g/kg over 5 daysGood improvement (Able to walk independently at discharge)
Cells = 5 cells/cmm; all lymphocytesNo Cord changes
No contrast enhancement
4Bilateral lower and midzone infiltratesPure motor demyelinating polyneuropathy involving all 4 limb and bifacial demyelinating neuropathy.Protein: 52 mg%;Mild degenerative changes.IVIG: 2 g/kg over 5 daysGood improvement (Able to walk independently at discharge)
Glucose: 54 mg%
Cells: <5 cells/cmm; all lymphocytesNo Cord changes
Clinical and laboratory parameters of four cases presenting with Covid-19 associated GBS. Laboratory parameters, Imaging and clinical outcomes of four cases presenting with Covid-19 associated GBS.

Case 2

A 72-year-old male, known case of hypertension for 5 years on treatment, presented to the emergency department of our hospital with chief complaints of fever 6 days back lasting for 2 days, cough since past 3 days associated with progressive weakness of all four limbs since past 2 days. He had lost the ability to walk independently since 1 day. There was no history suggestive of cranial nerve involvement, diarrhoea, bowel and bladder symptoms, or dog bite. On examination, patient was hemodynamically stable and afebrile. Neurological examination revealed no cranial nerve involvement. Motor examination showed generalised hypotonia, Grade 2/5 power in both lower limbs and grade 3/5 in both upper limbs as per MRC grading. Deep tendon reflexes were universally absent and plantar response was flexor bilaterally. The sensory examination was normal. His SBC was 12. His routine blood investigations including complete blood count, serum sodium and potassium, liver and kidney function tests were normal. Viral markers including Human Immunodeficiency Virus, Hepatitis B Surface antigen (HBsAg) and Hepatitis C Virus (HCV) antibody were negative. Serum B12 levels and Thyroid function tests were normal. Covid-19 testing was positive by RT-PCR technique. Contrast MRI of whole spine was suggestive of degenerative changes in the spine (Table 2). CSF examination showed albumino-cytological dissociation and inflammatory markers were elevated (Table 1, Table 2). Chest X ray showed bilateral ill-defined inhomogeneous infiltrates involving predominantly the upper lobes. IVIG therapy was started at a dose of 0.4 g/kg/day for five days. NCS was suggestive of severe demyelinating sensori-motor polyneuropathy affecting all 4 limbs with evidence of conduction block involving both ulnar nerves. Despite being on IVIG and supportive treatment for Covid-19, the patient had worsening of power in both upper and lower limbs and developed severe respiratory distress requiring intubation and mechanical ventilation. His respiratory involvement (chest infiltrates due to Covid-19) also continued to worsen and the patient expired after 7 days of hospital admission.

Case 3

A 55-year-old male, known case of Diabetes mellitus, hypertension and chronic kidney disease on maintenance haemodialysis (3/week) presented to OPD with chief complaints of difficulty in walking since 3 days and mild weakness of upper extremities since 1 day. He had history of cough and sore throat 1 week back for 2 days. There was no history suggestive of cranial nerve involvement, diarrhoea, bowel and bladder symptoms, or dog bite. On examination, patient was hemodynamically stable and afebrile. Neurological examination revealed no cranial nerve involvement. Motor examination showed generalised hypotonia, grade 3/5 power in both lower limbs proximally and 4−/5 distally. Upper limb motor examination showed grade 4/5 power bilaterally as per MRC grading. Deep tendon reflexes were absent in both lower limbs and 1+ in both upper limbs. Plantar response was flexor bilaterally. The sensory examination was abnormal with glove and stocking pattern sensory loss (position sense and pain) and positive Romberg's test. His SBC was 22. He underwent routine blood investigations which showed microcytic/hypochromic anaemia, raised blood Urea (61 mg/dL) and Creatinine levels (4.74 mg/dL). Potassium was elevated (5.82 mmol/L) with elevated HbA1c (8.4 %). Viral markers including HIV, HBsAg and HCV antibody were negative. Serum vitamin B12 levels and Thyroid function tests were normal. Covid-19 testing was positive by RT-PCR technique. MRI screening of whole spine showed mild degenerative changes with no cord hyperintensity (Table 2). CSF examination showed albumino-cytological dissociation with elevated inflammatory markers (Table 1, Table 2). Chest X ray was normal. NCS was suggestive of axonal sensorimotor polyneuropathy affecting all 4 limbs. IVIG therapy was started on Day 2 of hospital admission and 2 g/kg body weight of same was given over 5 days. Patient had good neurological improvement and was discharged by 9th day with power of grade 4+/5 in both upper limbs and grade 4/5 in both lower limbs.

Case 4

A 49-year-old male, known case of hypertension on treatment, presented to the neurology outpatient department (OPD) with chief complaints of fever 10 days back which lasted for 2 days followed by 4 days history of progressive lower limb weakness and 2 days history of facial weakness. On examination, patient was hemodynamically stable, afebrile with 98% SpO2 on room air. Neurological examination revealed bilateral lower motor neuron facial palsy (right > left). Upper limb power was normal across all joints; both lower limb power: proximal: 3/5; distal: 4/5 as per MRC grading. The Deep tendon reflexes were absent in lower limbs and normal in upper limbs. Sensory examination was normal. Routine blood investigations including complete blood count, serum sodium and potassium, liver and kidney function tests were normal. Viral markers including HIV, HBsAg and HCV antibody were negative. Serum vitamin B12 levels and Thyroid function tests were normal. Covid-19 testing was positive by RT-PCR technique. NCS was suggestive of pure motor demyelinating polyneuropathy involving all 4 limbs. Contrast MRI of whole spine showed mild degenerative changes of the spine (Table 2). CSF examination showed albumino-cytological dissociation with mildly elevated inflammatory markers in the blood (Table 1, Table 2). Chest X- ray showed evidence of bilateral lower and midzone infiltrates. IVIG was given at 0.4 g/kg body weight/day for 5 days with other supportive treatment. Good neurological improvement was observed over the next 5 days and patient was discharged after 7 days. At the time of discharge patient had 4+/5 power in both lower limbs with mild residual facial palsy.

Discussion

A member of the beta-coronaviridae family, SARS-CoV-2 is an enveloped, non-segmented, single-stranded, positive-sense RNA virus. The mechanisms by which SARS-CoV-2 causes neurologic damage are multifaceted, including direct damage to specific receptors, cytokine-related injury, secondary hypoxia, and retrograde travel along nerve fibres [5]. Three of the above cases presented with neurological complaints and had no respiratory features secondary to Covid-19, and these were the ones who did quite well with treatment. One patient who presented with respiratory complaints and X-ray changes along with neurological deficits continued to deteriorate even after starting treatment for both GBS and Covid-19, and eventually succumbed to the disease. In the past GBS has been associated with a number of viral infections, most recently to Zika virus [6]. The pathogenesis of GBS secondary to Covid-19 is not well understood. It is well documented that the cross immunity which plays an important role in GBS secondary to bacterial infections such as C. jejuni may not be the main reason behind GBS associated with viral infections namely Dengue and Zika. It is hypothesised that viral illnesses related GBS could be due to autoantibodies or direct neurotoxic effects of viruses [7]. Although, our patients had positive PCR throat swab test, their CSF examination did not show any raised cell count and contrast MRI of the spine did not show any enhancement of caudal nerve roots, thus favouring immune mediated hypothesis. This was further strengthened by an excellent response to IVIG, thus favouring an immune mediated pathogenesis rather than direct viral damage. Our case series serves to highlight the heterogeneity in clinical presentation and laboratory parameters of patients with Covid-19 associated GBS (Tables1 and 2). Only one of our patients had cranial nerve involvement (bilateral facial nerve palsy) with no patient developing bulbar symptoms. This was in contrast to typical GBS, wherein cranial nerve involvement is quite common. Less frequent involvement of cranial nerves in GBS secondary to Covid-19 is also in contrast to Zika virus associated GBS, where facial and third nerve involvement was quite common [7]. All the above patients had significantly raised pro-inflammatory markers that might suggest a causal link to pro-inflammatory state secondary to Covid-19. Similar rise in inflammatory markers were noted in other case reports as well, and it was hypothesised that these inflammatory mediators and cytokines may play a role in triggering an immune mediated neuropathy [8]. All our patients developed features of GBS, 5–10 days after the onset of Covid-19 symptoms, which is similar to the interval seen with Guillain–Barré syndrome that occurs secondary to other infections [9]. Most of the previous case reports documented a similar interval duration between the onset of Covid-19 symptoms and GBS [2,9]. Three of our patients had an excellent response to IVIG and were ambulatory without support within 10 days of starting treatment. Previous case reports show mixed treatment response with some reporting very good recovery, while others reported minimal or delayed response [9,10].

Conclusion

Nervous system involvement in Covid-19 may have been grossly underestimated. Over the course of this pandemic, an increasing number of Covid-19 patients are being reported with neurological complications. Some of these neurological presentations, in particular GBS has quite effective treatment options. In this era of pandemic, it is very important for the physicians to be aware of the association of GBS with Covid-19, as early diagnosis and treatment of this complication could have gratifying results. It is also important to differentiate GBS from critical illness neuropathy and respiratory distress secondary to Covid-19 itself, as treatment to the above conditions is quite different and inability to correctly diagnose could lead to significant increase in morbidity and mortality. To the best of our knowledge this case series of Guillain-Barre Syndrome associated with Covid-19 is the first one to be reported from India.

Declaration of Competing Interest

The manuscript, as submitted or its essence in another version, is not under consideration for publication elsewhere, and will not be published elsewhere while under consideration by AJEM. The authors have no commercial associations or sources of support that might pose a conflict of interest. All authors have made substantive contributions to the study, and all authors endorse the data and conclusions.
  7 in total

1.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.

Authors:  Ling Mao; Huijuan Jin; Mengdie Wang; Yu Hu; Shengcai Chen; Quanwei He; Jiang Chang; Candong Hong; Yifan Zhou; David Wang; Xiaoping Miao; Yanan Li; Bo Hu
Journal:  JAMA Neurol       Date:  2020-06-01       Impact factor: 18.302

Review 2.  Neurologic complications of COVID-19.

Authors:  Rachel Bridwell; Brit Long; Michael Gottlieb
Journal:  Am J Emerg Med       Date:  2020-05-16       Impact factor: 2.469

3.  Guillain-Barré Syndrome associated with SARS-CoV-2 infection.

Authors:  Ahmed Virani; Erica Rabold; Taylor Hanson; Aaron Haag; Rawiya Elrufay; Tariq Cheema; Marvin Balaan; Nitin Bhanot
Journal:  IDCases       Date:  2020-04-18

4.  Is COVID-19-related Guillain-Barré syndrome different?

Authors:  Ankit Gupta; Vimal Kumar Paliwal; Ravindra Kumar Garg
Journal:  Brain Behav Immun       Date:  2020-05-20       Impact factor: 7.217

5.  Guillain-Barré Syndrome Associated with SARS-CoV-2.

Authors:  Gianpaolo Toscano; Francesco Palmerini; Sabrina Ravaglia; Luigi Ruiz; Paolo Invernizzi; M Giovanna Cuzzoni; Diego Franciotta; Fausto Baldanti; Rossana Daturi; Paolo Postorino; Anna Cavallini; Giuseppe Micieli
Journal:  N Engl J Med       Date:  2020-04-17       Impact factor: 91.245

6.  New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases.

Authors:  Andrea Assini; Luana Benedetti; Silvia Di Maio; Erika Schirinzi; Massimo Del Sette
Journal:  Neurol Sci       Date:  2020-05-28       Impact factor: 3.307

  7 in total
  14 in total

1.  Guillian--Barre' Syndrome in Patients with SARS-CoV-2: A Multicentric Study from Maharashtra, India.

Authors:  Megha C Dhamne; Rajesh Benny; Rakesh Singh; Amitkumar Pande; Pankaj Agarwal; Satish Wagh; Pradyumna Oak; Akshay Lakhotia; Yogesh Godge; Vyankatesh Bolegave; Darshan Doshi; Yogesh Patidar; Anil Venkatachalam; Bhavin Pujara; Sandeep Borse; Prashant Makhija; Satish Khadilkar
Journal:  Ann Indian Acad Neurol       Date:  2021-07-09       Impact factor: 1.383

2.  Age-Associated Neurological Complications of COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Brianne N Sullivan; Tracy Fischer
Journal:  Front Aging Neurosci       Date:  2021-08-02       Impact factor: 5.750

Review 3.  Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: A systematic review and meta-analysis.

Authors:  Lina Palaiodimou; Maria-Ioanna Stefanou; Aristeidis H Katsanos; Paraskevi C Fragkou; Marianna Papadopoulou; Christos Moschovos; Ioannis Michopoulos; Panagiotis Kokotis; Christos Bakirtzis; Androniki Naska; Theodoros I Vassilakopoulos; Elisabeth Chroni; Sotirios Tsiodras; Georgios Tsivgoulis
Journal:  Eur J Neurol       Date:  2021-04-28       Impact factor: 6.288

Review 4.  Cerebrospinal fluid in COVID-19: A systematic review of the literature.

Authors:  Ariane Lewis; Jennifer Frontera; Dimitris G Placantonakis; Jennifer Lighter; Steven Galetta; Laura Balcer; Kara R Melmed
Journal:  J Neurol Sci       Date:  2021-01-10       Impact factor: 3.181

Review 5.  Guillain-Barré syndrome in low-income and middle-income countries: challenges and prospects.

Authors:  Nowshin Papri; Zhahirul Islam; Sonja E Leonhard; Quazi D Mohammad; Hubert P Endtz; Bart C Jacobs
Journal:  Nat Rev Neurol       Date:  2021-03-01       Impact factor: 42.937

6.  Guillain-Barré Syndrome Associated with SARS-CoV-2 Infection.

Authors:  Kokil Y Das; K T Midhun Raj; Madhusudan Samprathi; M Sridhar; Rashmi Adiga; Prakash Vemgal
Journal:  Indian J Pediatr       Date:  2021-02-09       Impact factor: 1.967

Review 7.  Guillain-Barré Syndrome in the COVID-19 Pandemic.

Authors:  Abdullah Ahmad Tawakul; Amal Waleed Al-Doboke; Shahad Ali Altayyar; Seham Abdulhafith Alsulami; Ahlam Musallam Alfahmi; Raghad Turki Nooh
Journal:  Neurol Int       Date:  2021-12-24

8.  Post-COVID-19 Guillain-Barré Syndrome: A Case Report With Literature Review.

Authors:  Nidhi Kaeley; Ankita Kabi; Aadya Pillai; Takshak Shankar; Salva Ameena M S
Journal:  Cureus       Date:  2022-01-14

9.  Guillain Barré syndrome associated with COVID-19- lessons learned about its pathogenesis during the first year of the pandemic, a systematic review.

Authors:  Mayka Freire; Ariadna Andrade; Bernardo Sopeña; Maria Lopez-Rodriguez; Pablo Varela; Purificación Cacabelos; Helena Esteban; Arturo González-Quintela
Journal:  Autoimmun Rev       Date:  2021-06-10       Impact factor: 9.754

Review 10.  Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic.

Authors:  Saikat Dewanjee; Jayalakshmi Vallamkondu; Rajkumar Singh Kalra; Nagaprasad Puvvada; Ramesh Kandimalla; P Hemachandra Reddy
Journal:  Mol Neurobiol       Date:  2021-06-24       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.